%0 Journal Article
%A Pulido, Federico
%A Ribera, Esteban
%A Lagarde, Maria
%A Perez-Valero, Ignacio
%A Palacios, Rosario
%A Iribarren, Jose A.
%A Payeras, Antoni
%A Domingo, Pere
%A Sanz, Jose
%A Cervero, Miguel
%A Curran, Adrian
%A Rodriguez-Gomez, Francisco J.
%A Tellez, Maria J.
%A Ryan, Pablo
%A Barrufet, Pilar
%A Knobel, Hernando
%A Rivero, Antonio
%A Alejos, Belen
%A Yllescas, Maria
%A Arribas, Jose R.
%A DUAL-GESIDA-8014-RIS-EST45 Study G
%T Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial
%D 2017
%@ 1058-4838
%U http://hdl.handle.net/10668/18942
%X Background. Our objective was to assess the therapeutic noninferiority of dual therapy with darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.Methods. This was a multicenter, open-label, noninferiority trial (margin 12%). Patients with HIV-1 RNA
%K darunavir/ritonavir
%K lamivudine
%K switch
%K dual therapy
%K Non-inferiority trial
%K Reverse-transcriptase inhibitor
%K Virologically stable patients
%K Boosted protease inhibitor
%K Antiretroviral therapy
%K Coformulated elvitegravir
%K 2 nucleos(t)ides
%K Phase 3b
%K Simplification
%K Hiv
%~